Fresenius Kabi Oncology Limited

Fresenius Kabi Ipsum S.r.l.

Govind Singh

Walter Cabri

Saswata Lahiri

Raj Narayan Tiwari

Sarbjot Singh Sokhi

Maneesh Kumar Pandey

Jacopo Zanon

Antonio Ricci

Sonu Prasad Shukla

Shivaji Haribhau Shelke

Nitin Kumar

Hrishikesh Acharya

Sridhar Reddy Male

Saurabh Upadhyay

Madan Singh

Suneel Kumar Sharma

Dominik Heckmann

Sachin Musmade

Heena Dua

Tapanjyoti Biswal

Shridhar Reddy

The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Polymorphic forms of Belinostat and processes for preparation thereof

The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PGmay be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC. 

Process for the preparation of boronic acid esters

The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer. 

Process for the preparation of ribociclib and its salts

The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib. 

Process for purification of carfilzomib intermediate

Polymorphic forms of belinostat and processes for preparation thereof

The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-&#x3b3;-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.

Process for the preparation of sugammadex

The present application provides crystalline forms of 6-per-deoxy-6-per-chloro-&#x3b3;-cyclodextrin, and polymorphs thereof. The present application also provides methods for preparing said polymorphs by dissolving 6-per-deoxy-6-per-chloro-&#x3b3;-cyclodextrin in dimethylformamide and using an anti-solvent of a water/alcohol mixture.

Crystalline forms of per-chloro-&#x3b3;-cyclodextrines

The present application provides an improved process for the preparation of sugammadex which comprises the halogenation of &#x3b3;-cyclodextrin in a suitable organic solvent to give 6-per-deoxy-6-per-halo-&#x3b3;-cyclodextrin, wherein halo is bromo or chloro, reacting the halogenated &#x3b3;-cyclodextrin with 3-mercaptopropionic acid in the presence of alkoxide base to obtain sugammadex of formula I. This application also provides isolation of 6-per-deoxy-6-per-chloro-&#x3b3;-cyclodextrin as a crystalline compound and its use for the preparation of sugammadex of formula (I).

Process for the preparation of sugammadex and its intermediates

The present invention relates to a process for the purification of Carfilzomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt %. 

Process for purification of Carfilzomib

Growing community of inventors

Ghaziabad, India

Govind Singh